Bausch + Lomb Q3 revenue $1.007B, raises full-year 2023 revenue and EBITDA guidance

Bausch & Lomb Corp

2023-Q3 EPS reported -$0.59 revenue$2,973,000,000

Q3 revenue $1.007B (+7% YoY, +8% constant currency); GAAP net loss of $84M vs $18M loss prior year.
Adjusted EBITDA $187M (flat YoY); adjusted EPS $0.22 (vs $0.31 prior year).
Full-year 2023 revenue guidance raised to $4.035-$4.085B; Adjusted EBITDA guidance raised to $710-$760M.
Vision Care revenue rose 9% to $648M; Surgical up 8% to $185M; Pharmaceuticals flat at $174M.
Launched MIEBO for dry eye and acquired XIIDRA; distribution system upgrade impacted contact lens sales, expected to resolve in Q1 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Bausch & Lomb Corp reported the quarter ended September 30, 2023 results: revenue $1.007 billion, net income $84 million. Guidance raised.

Period: the quarter ended September 30, 2023
Revenue: $1.007 billion
Net income: $84 million
Guidance: raised
Result: reported results

Exact text from the filing

to the Securities Act of 1933, as amended. --- EX-99.1 (EX-99.1) --- Bausch + Lomb Announces Third-Quarter 2023 Results and Raises Full-Year 2023 Guidance • Revenues of $1.007 Billion • GAAP Net Loss Attributable to Bausch + Lomb Corporation of $84 Million • Adjusted EBITDA (non-GAAP) 1 of $187 Million • Revenues Grew 7% as Reported and 8% on a Constant

View on SEC.gov

Browse all earnings releases →

Bausch & Lomb Corp filing history →

Source: SEC EDGAR

accession 0001860742-23-000026

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.